Bancreek Capital Management LP Makes New Investment in Boston Scientific Corporation $BSX

Bancreek Capital Management LP purchased a new stake in Boston Scientific Corporation (NYSE:BSX) in the 1st quarter, HoldingsChannel reports. The fund purchased 39,000 shares of the medical equipment provider’s stock, valued at approximately $2,447,000. Boston Scientific accounts for approximately 10.6% of Bancreek Capital Management LP’s portfolio, making the stock its 6th biggest holding.

A number of other institutional investors and hedge funds also recently made changes to their positions in BSX. FWL Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at about $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the fourth quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific in the fourth quarter valued at approximately $26,000. Bangor Savings Bank increased its holdings in shares of Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares in the last quarter. Finally, Board of the Pension Protection Fund bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $29,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 3.6%

BSX stock opened at $44.58 on Friday. The firm has a market capitalization of $66.26 billion, a PE ratio of 18.65, a P/E/G ratio of 0.82 and a beta of 0.58. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The stock’s 50 day moving average is $48.38 and its 200-day moving average is $66.02.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a stock buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Robert W. Baird set a $70.00 target price on Boston Scientific in a report on Thursday, May 28th. Canaccord Genuity Group decreased their price target on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Raymond James Financial restated an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a research note on Thursday, May 28th. Finally, Evercore set a $65.00 price objective on shares of Boston Scientific in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $79.84.

Insiders Place Their Bets

In other news, Director David C. Habiger bought 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Cheryl Pegus bought 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the acquisition, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 9,800 shares of company stock valued at $554,012 in the last three months. 0.34% of the stock is currently owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.